Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza HA stem vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Quadrivalent influenza HA stem vaccine (SteMos1, VRC-FLUMOS0122-00-VP) is an investigational universal influenza vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is designed as a self-assembling nanoparticle that projects 20 stabilized hemagglutinin (HA) stem trimers from four different influenza A strains representing both Group 1 (H2, H5) and Group 2 (H7, H10) viruses. By targeting the highly conserved stem region of the hemagglutinin protein rather than the rapidly mutating head region, SteMos1 aims to elicit broad, durable, and cross-protective immune responses against multiple seasonal and potentially pandemic influenza strains. It is currently being evaluated in Phase 1 clinical trials, both alone and in combination with the Army Liposome Formulation containing saponin QS-21 (ALFQ) adjuvant.
- Other names
- quadrivalent influenza hemagglutinin stem vaccinestem quadrivalent influenza vaccine
02
Targets
HA stem (Influenza A hemagglutinin stem region)
Beyond the preview
Go deeper on quadrivalent influenza HA stem vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza HA stem vaccine.